헬리코박터 파일로리 진단 시장 분석 보고서 : 유형별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Helicobacter Pylori Diagnostics Market Growth & Trends:

The global helicobacter pylori diagnostics market size is anticipated to reach USD 966.19 million by 2030, expanding at a CAGR of 5.87% from 2025 to 2030, according to a new report by Grand View Research. Increasing demand for personalized antibiotic therapy coupled with improved cost-effectiveness Helicobacter pylori (H. pylori) infection diagnosis is projected to drive the growth.

Easy accessibility and affordability of antibiotics along with short treatment durations will boost the adoption of antibiotics as well as the demand for pre and post monitoring tests. Furthermore, factors such as rising incidence of H. pylori infections, need for early diagnosis, and rapid technological advancements in diagnostic techniques will propel the market growth. However, rising pressure of maintaining economic pricing due to the extremely competitive environment may hinder the growth of the Helicobacter pylori diagnostics market.

H. pylori is an aerobic gram-negative bacteria generally found in the stomach. Although advantageous for balancing the stomach ecology, it can cause infection to the inner stomach lining. The bacteria can act as one of the causative agents for stomach cancer, duodenal ulcers, gastritis and gastric ulcers, and infection to the small intestine, among other conditions. This has led to an increase in the demand for Helicobacter pylori diagnostics that enable early detection of H. pylori infection. Patients are subject to an antibiotic therapy for 10 to 14 days, in case of positive diagnosis of ulcers caused by this bacteria. Treatment for H. pylori could include a combination of antibiotics such as metronidazole, amoxicillin, clarithromycin, tetracycline, or with a proton pump inhibitor, ranitidine bismuth citrate, and bismuth subsalicylate.

The immunoassay technology segment held the largest market share in 2018 and is expected to register the fastest CAGR over the forecast period. In terms of end user, the hospital segment held the largest market share in 2018, while diagnostic laboratories is anticipated to expand at the fastest CAGR in the forthcoming years. In terms of region, North America led the global market for Helicobacter pylori diagnostics. Asia Pacific, on the other hand, is expected to witness the fastest CAGR from 2019 to 2026.

Helicobacter Pylori Diagnostics Market Report Highlights:

• Immunoassays technology held the largest market share in 2024 and is expected to witness the fastest CAGR over the forecast period
• Among end user, hospital segment held the largest market share in 2024, while the diagnostics laboratories segment is expected to demonstrate the fastest CAGR from 2025 to 2030
• Latin America is anticipated to grow at the fastest CAGR of 6.4% in the forecast period owing to the rising importance to the healthcare sector, increasing infectious diseases prevalence, and awareness.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Information Procurement
• 1.2. Information or Data Analysis
• 1.3. Market Scope & Segment Definition
• 1.4. Market Model
  • 1.4.1. Market Study, By Company Market Share
  • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
• 3.5. Market Restraint Analysis
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Type Business Analysis

• 4.1. Helicobacter Pylori Diagnostics Market: Type Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
• 4.3. Reagents
  • 4.3.1. Reagents Market, 2018 - 2030 (USD Million)
• 4.4. Services
  • 4.4.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Helicobacter Pylori Diagnostics Market: Technology Movement Analysis
• 5.2. Immunoassays
  • 5.2.1. Immunoassays Market, 2018 - 2030 (USD Million)
• 5.3. POC
  • 5.3.1. POC Market, 2018 - 2030 (USD Million)
• 5.4. Molecular Diagnostics
  • 5.4.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 6. End use Business Analysis

• 6.1. Helicobacter Pylori Diagnostics Market: End use Movement Analysis
• 6.2. Hospitals
  • 6.2.1. Hospitals Market, 2018 - 2030 (USD Million)
• 6.3. Diagnostics Laboratories
  • 6.3.1. Diagnostics Laboratories Market, 2018 - 2030 (USD Million)
• 6.4. Clinics
  • 6.4.1. Clinics Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

• 7.1. Helicobacter Pylori Diagnostics Market Share By Region, 2024 & 2030
• 7.2. North America
  • 7.2.1. North America Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Target Disease Prevalence
    • 7.2.2.3. Competitive Scenario
    • 7.2.2.4. Regulatory Framework
    • 7.2.2.5. Reimbursement Scenario
    • 7.2.2.6. U.S. Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Target Disease Prevalence
    • 7.2.3.3. Competitive Scenario
    • 7.2.3.4. Regulatory Framework
    • 7.2.3.5. Reimbursement Scenario
    • 7.2.3.6. Canada Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.2.4. Mexico
    • 7.2.4.1. Key Country Dynamics
    • 7.2.4.2. Target Disease Prevalence
    • 7.2.4.3. Competitive Scenario
    • 7.2.4.4. Regulatory Framework
    • 7.2.4.5. Reimbursement Scenario
    • 7.2.4.6. Mexico Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.3.2. Germany
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Target Disease Prevalence
    • 7.3.2.3. Competitive Scenario
    • 7.3.2.4. Regulatory Framework
    • 7.3.2.5. Reimbursement Scenario
    • 7.3.2.6. Germany Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.3.3. UK
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Regulatory Framework
    • 7.3.3.5. Reimbursement Scenario
    • 7.3.3.6. UK Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target Disease Prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. Regulatory Framework
    • 7.3.4.5. Reimbursement Scenario
    • 7.3.4.6. France Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Target Disease Prevalence
    • 7.3.5.3. Competitive Scenario
    • 7.3.5.4. Regulatory Framework
    • 7.3.5.5. Reimbursement Scenario
    • 7.3.5.6. Italy Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Target Disease Prevalence
    • 7.3.6.3. Competitive Scenario
    • 7.3.6.4. Regulatory Framework
    • 7.3.6.5. Reimbursement Scenario
    • 7.3.6.6. Spain Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Target Disease Prevalence
    • 7.3.7.3. Competitive Scenario
    • 7.3.7.4. Regulatory Framework
    • 7.3.7.5. Reimbursement Scenario
    • 7.3.7.6. Denmark Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Target Disease Prevalence
    • 7.3.8.3. Competitive Scenario
    • 7.3.8.4. Regulatory Framework
    • 7.3.8.5. Reimbursement Scenario
    • 7.3.8.6. Sweden Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Target Disease Prevalence
    • 7.3.9.3. Competitive Scenario
    • 7.3.9.4. Regulatory Framework
    • 7.3.9.5. Reimbursement Scenario
    • 7.3.9.6. Norway Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. Regulatory Framework
    • 7.4.2.5. Reimbursement Scenario
    • 7.4.2.6. Japan Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Regulatory Framework
    • 7.4.3.5. Reimbursement Scenario
    • 7.4.3.6. China Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. Regulatory Framework
    • 7.4.4.5. Reimbursement Scenario
    • 7.4.4.6. India Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Regulatory Framework
    • 7.4.5.5. Reimbursement Scenario
    • 7.4.5.6. South Korea Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Regulatory Framework
    • 7.4.6.5. Reimbursement Scenario
    • 7.4.6.6. Australia Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. Regulatory Framework
    • 7.4.7.5. Reimbursement Scenario
    • 7.4.7.6. Thailand Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. Regulatory Framework
    • 7.5.2.5. Reimbursement Scenario
    • 7.5.2.6. Brazil Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.5.3. Argentina
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Regulatory Framework
    • 7.5.3.5. Reimbursement Scenario
    • 7.5.3.6. Argentina Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. Regulatory Framework
    • 7.6.2.5. Reimbursement Scenario
    • 7.6.2.6. South Africa Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Regulatory Framework
    • 7.6.3.5. Reimbursement Scenario
    • 7.6.3.6. Saudi Arabia Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. Regulatory Framework
    • 7.6.4.5. Reimbursement Scenario
    • 7.6.4.6. UAE Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Regulatory Framework
    • 7.6.5.5. Reimbursement Scenario
    • 7.6.5.6. Kuwait Helicobacter pylori diagnostics Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Share Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Biohit Oyj
    • 8.4.1.1. Overview
    • 8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.1.3. Collection Site Benchmarking
    • 8.4.1.4. Strategic Initiatives
  • 8.4.2. Thermo Fisher Scientific, Inc.
    • 8.4.2.1. Overview
    • 8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.2.3. Collection Site Benchmarking
    • 8.4.2.4. Strategic Initiatives
  • 8.4.3. Quest Diagnostics Incorporated
    • 8.4.3.1. Overview
    • 8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.3.3. Collection Site Benchmarking
    • 8.4.3.4. Strategic Initiatives
  • 8.4.4. Meridian Bioscience
    • 8.4.4.1. Overview
    • 8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.4.3. Collection Site Benchmarking
    • 8.4.4.4. Strategic Initiatives
  • 8.4.5. Bio-Rad Laboratories
    • 8.4.5.1. Overview
    • 8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.5.3. Collection Site Benchmarking
    • 8.4.5.4. Strategic Initiatives
  • 8.4.6. Alpha Laboratories Ltd
    • 8.4.6.1. Overview
    • 8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.6.3. Collection Site Benchmarking
    • 8.4.6.4. Strategic Initiatives
  • 8.4.7. Coris BioConcept
    • 8.4.7.1. Overview
    • 8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.7.3. Collection Site Benchmarking
    • 8.4.7.4. Strategic Initiatives
  • 8.4.8. F. Hoffmann-La Roche AG
    • 8.4.8.1. Overview
    • 8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.8.3. Collection Site Benchmarking
    • 8.4.8.4. Strategic Initiatives
  • 8.4.9. Certest Biotec
    • 8.4.9.1. Overview
    • 8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.9.3. Collection Site Benchmarking
    • 8.4.9.4. Strategic Initiatives
  • 8.4.10. Epitope Diagnostics, Inc.
    • 8.4.10.1. Overview
    • 8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.4.10.3. Collection Site Benchmarking
    • 8.4.10.4. Strategic Initiatives